Cite

    Uchida, T., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Hashimoto, K., Nishihara, F., Murayama, Y., Kobayashi, K., & Kagamu, H. (2019). different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer. Thoracic cancer, 10(4), 975–979. http://access.bl.uk/ark:/81055/vdc_100080189061.0x00000c